Literature DB >> 10417456

Dosage of neostigmine for reversal of rocuronium block from two levels of spontaneous recovery.

K C McCourt1, R K Mirakhur, C M Kerr.   

Abstract

Spontaneous recovery, and recovery following neostigmine 20, 35 or 50 microgram.kg-1 administered at 10 or 25% of recovery of the first twitch of the train-of-four, was assessed in 80 patients after rocuronium administration under continued isoflurane anaesthesia. In an additional 40 patients, isoflurane administration was discontinued and neostigmine 35 or 50 microgram.kg-1 was given at 10 or 25% recovery. The administration of neostigmine reduced the recovery times significantly. A neostigmine dose of 20 microgram.kg-1 resulted in slower recovery compared with the higher doses, particularly when reversal was attempted at a first twitch height of 10%. Higher doses of neostigmine given at a first twitch height of 25% resulted in rapid reversal of block [mean (SD) times of 7.0 (4.8) and 6.4 (1.9) min with the 35 and 50 microgram.kg-1 doses, respectively, for attaining a train-of-four ratio of 0.8]. Discontinuing isoflurane did not alter recovery times. The incidence of emetic symptoms did not differ between groups, including one group that received atropine instead of glycopyrronium in combination with neostigmine. We conclude that rocuronium block can be antagonised safely using a neostigmine dose of 35 microgram.kg-1, although recovery may be slightly slower if administered at a first twitch of 10% of control.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417456     DOI: 10.1046/j.1365-2044.1999.00893.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  6 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Anesthesia and fast-track in video-assisted thoracic surgery (VATS): from evidence to practice.

Authors:  Marzia Umari; Stefano Falini; Matteo Segat; Michele Zuliani; Marco Crisman; Lucia Comuzzi; Francesco Pagos; Stefano Lovadina; Umberto Lucangelo
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Effects of Sugammadex and Neostigmine on Post-operative Nausea and Vomiting in ENT Surgery.

Authors:  Nik Izyan Syaizana Nik Mat; Chih Nie Yeoh; Muhammad Maaya; Jaafar Md Zain; Joanna Su Min Ooi
Journal:  Front Med (Lausanne)       Date:  2022-05-20

4.  Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?

Authors:  Ching-Rong Cheng; Daniel I Sessler; Christian C Apfel
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 6.627

5.  Sugammadex versus two doses of neostigmine for reversal of rocuronium in gastric sleeve surgery.

Authors:  Abdulhamid Alsaeed; Fahad Bamehriz; Sharaf Eldin; Tareq Alzahrani; Abdullah Alharbi; Abdelazeem Eldawlatly
Journal:  Saudi J Anaesth       Date:  2017 Jul-Sep

6.  Sugammadex to reverse neuromuscular blockade and provide optimal conditions for motor-evoked potential monitoring.

Authors:  Mehdi Trifa; Senthil Krishna; Ajay D'Mello; Mumin Hakim; Joseph Drew Tobias
Journal:  Saudi J Anaesth       Date:  2017 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.